Related Experiment Video

Updated: Jun 4, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Mechanisms of resistance to BCR-ABL kinase inhibitors

Joana M Diamond1, Junia V Melo

  • 1Hemato-Oncology Laboratory, Molecular Biology Unit, Instituto Português de Oncologia, Lisbon, Portugal.

Leukemia & Lymphoma
|February 9, 2011
PubMed

Insights

This review covers why chronic myeloid leukemia (CML) cells develop resistance to tyrosine kinase inhibitors (TKIs). Understanding TKI resistance mechanisms is crucial for improving CML treatment outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Imatinib mesylate (IM) and second-generation tyrosine kinase inhibitors (TKIs) have significantly improved chronic myeloid leukemia (CML) treatment.
  • However, suboptimal responses, treatment failure, and sustained remission challenges persist in a subset of CML patients.
  • The development of resistance to TKIs is a major obstacle in achieving long-term disease control.

Purpose of the Study:

  • To review the current understanding of the mechanisms underlying TKI resistance in CML.
  • To explore the reasons for both primary and acquired resistance to TKIs in CML patients.
  • To discuss the implications of TKI resistance for CML management and future therapeutic strategies.

Main Methods:

  • This review synthesizes existing research on TKI resistance in CML.
  • It analyzes studies investigating the molecular pathways and genetic alterations associated with resistance.
  • The review consolidates findings on clinical observations and experimental data regarding resistance mechanisms.

Main Results:

  • CML cells develop resistance through various mechanisms, including BCR-ABL mutations and activation of alternative signaling pathways.
  • Primary resistance occurs when CML cells are inherently less sensitive to TKIs.
  • Acquired resistance emerges during treatment due to the selection of resistant clones or the development of new resistance mechanisms.

Conclusions:

  • Understanding the diverse mechanisms of TKI resistance is essential for developing effective CML treatment strategies.
  • Further research is needed to identify novel therapeutic targets and combination therapies to overcome resistance.
  • Strategies to manage TKI resistance are critical for improving long-term outcomes in CML patients.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...